Side-by-side · Research reference

BronchogenvsGHK-Cu

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/35 cited

BHuman-MechanisticHUMAN-REVIEWED8/47 cited

Bronchogen

Tetrapeptide Bioregulator · Khavinson-School

0.05 ng/mLEffective concentrationZakutskiĭ 2006

60 daysCOPD model durationTitova 2017

30 daysTreatment courseKuzubova 2015

Research models: tissue culture / parenteral

GHK-Cu

Tripeptide · Skin / Hair / Wound Healing

1–2 mgSQ dosePickart 2018

HumanMechanisticPickart 2018 Zink 2003

HoursHalf-life

SQ or topical · Local · Daily or 2-3×/week

01Mechanism of Action

Parameter

Bronchogen

GHK-Cu

Primary target

Bronchial epithelial cellsKuzubova 2015

Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018

Pathway

Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration

Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018

Downstream effect

Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015 Titova 2017

Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018 Zink 2003

Feedback intact?

—

Replaces declining endogenous levels

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework

Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018

Antibody development

—

02Dosage Protocols

Parameter

Bronchogen

GHK-Cu

Effective concentration (culture)

0.05 ng/mLZakutskiĭ 2006

Demonstrated in organotypic tissue culture of bronchial explants.

—

Treatment duration (animal)

1 month (30 days)Kuzubova 2015 Titova 2017

Course duration in rat COPD models.

—

Evidence basis

Animal models (rat) / organotypic cultureTitova 2017 Kuzubova 2015 Zakutskiĭ 2006

No human clinical trials reported in available literature.

Human-mechanistic + topical clinical studiesPickart 2018

Model system

NO₂-induced COPD (60-day intermittent exposure)Titova 2017

—

Tissue specificity

Selective for bronchopulmonary tissue

Part of Khavinson organ-specific bioregulator series.

—

Standard SQ dose

—

1–2 mg / dayPickart 2018

Anecdotal injectable range; topical creams use 0.1–2% solutions.

Topical concentration

—

0.1–2.0% in serum / cream

Frequency

—

Daily or 2–3× per week (SQ)

Lower / starter dose

—

0.5 mg / day SQ

Duration

—

8–12 weeks for visible skin / hair effect

Reconstitution

—

Bacteriostatic water; light-protected

Timing

—

No specific time; evening preferred for topicals

Half-life

—

Hours (estimated; rapid tissue uptake)

04Side Effects & Safety

Parameter

Bronchogen

GHK-Cu

Animal safety profile

No adverse effects reported in published rat studies

Limited safety data; only animal models available.

—

Human data

Absent — no clinical trials in humans reported

—

Long-term effects

Unknown — maximum study duration 30 days in animals

—

Injection site reaction

—

Erythema, mild pruritus (common)

Topical irritation

—

Mild redness, transient stinging

Copper accumulation

—

Theoretical with very high chronic doses

Allergic reaction

—

Rare hypersensitivity to copper

Pregnancy / OB

—

Avoid topical and SQ — insufficient data

Wilson disease

—

Contraindicated

Absolute Contraindications

Bronchogen

—

GHK-Cu

·Wilson disease (copper-overload disorder)
·Pregnancy / breastfeeding
·Known copper hypersensitivity

Relative Contraindications

Bronchogen

—

GHK-Cu

·Hemochromatosis (copper-iron crosstalk theoretical)
·Concurrent copper-chelator therapy

05Administration Protocol

Parameter

Bronchogen

GHK-Cu

1. Research context only

Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.

Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.

2. Animal model protocol

In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017 Kuzubova 2015

SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.

3. Organotypic culture

Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006

Anytime; evening preferred. Topical: apply to clean dry skin.

4. Khavinson bioregulator tradition

Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.

5. Needle

—

30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.

06Stack Synergy

Bronchogen

— no documented stacks

GHK-Cu

+ BPC-157

Moderate

View BPC-157 →

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu: 1–2 mg SQ · daily near wound
BPC-157: 250–500 mcg SQ · daily near wound
Primary benefit: Combined ECM rebuilding + angiogenesis for tissue repair